MedTrace Logo

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

NCT07227415 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 224

Last updated 2026-05-22

No results posted yet for this study

Summary

This study is testing a new medicine called PF-08634404 and how it works in adults with advanced Renal Cell Carcinoma (RCC)- a type of kidney cancer that is either locally advanced (spread to nearby tissues) or metastatic (spread to other parts of the body). The study will look at the safety of the study medicine, when given alone or with other anticancer medicines, and how this type of cancer responds to them.

To join the study, participants must be adults; with locally advanced or metastatic RCC; who have not received treatment for their advanced kidney cancer.

Participants will receive study medicine either alone or with other anticancer medicines. The medicine will be given through intravenous (IV) infusions, which means it will be injected directly into a vein. All treatments will take place at clinical study sites, where trained medical staff will take care of participants during and after each visit.

Conditions

  • Carcinoma, Renal Cell
  • Advanced Renal Cell Carcinoma
  • Renal Cancer
  • Renal Neoplasm
  • Clear Cell Renal Cell Carcinoma
  • Metastatic Renal Cell Carcinoma
  • Clear-cell Metastatic Renal Cell Carcinoma
  • Carcinoma, Renal Cell Metastasis
  • Advanced or Metastatic Renal Cell Carcinoma
  • Carcinoma, Renal Cell, Advanced
  • Metastatic Renal Cell Cancer
  • Metastatic Renal Cell Carcinoma ( mRCC)
  • Metastatic/Advanced Renal Cell Carcinoma

Interventions

DRUG

PF-08634404

Concentrate for solution for infusion

DRUG

Ipilimumab

Solution for infusion

DRUG

Axitinib

Tablet

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-10
Primary Completion
2027-11-02
Completion
2028-11-01
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Japan

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07227415 on ClinicalTrials.gov